COMMUNIQUÉS West-GlobeNewswire

New Data Presented on ASLAN’s varlitinib at ESMO Show Promising Results in Heavily Pre-Treated BTC and CRC Patients
22/10/2018
SINGAPORE, Oct. 22, 2018 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (NASDAQ:ASLN, TPEx:6497), a clinical-stage biopharmaceutical company targeting cancers that are both highly prevalent in Asia and orphan indications in [...]
ESMO 2018: Athenex Presented Encouraging Clinical Trial Efficacy and Safety Results of Oraxol in the Treatment of Metastatic Breast Cancer
22/10/2018
BUFFALO, N.Y., Oct. 22, 2018 (GLOBE NEWSWIRE) -- Athenex (Nasdaq: ATNX), a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies for the treatment of cancer [...]
Immunicum AB (publ) Presents Preclinical Results of Ilixadencel in Combination with Checkpoint Inhibitors and Immune Enhancers at ESMO 2018
22/10/2018
Press Release 22 October 2018 Immunicum AB (publ) Presents Preclinical Results of Ilixadencel in Combination with Checkpoint Inhibitors and Immune Enhancers at ESMO 2018 -- Intratumoral treatment with ilixadencel, an [...]
CytomX Therapeutics Presents Clinical Data from Probody™ Platform and CX-072 at 2018 ESMO Annual Meeting
22/10/2018
- Additional Data Supports PD-L1 Targeting Probody CX-072 as Well Tolerated with Antitumor Activity as Monotherapy and in Combination with Ipilimumab - - Company to Host Conference Call and Webcast Today, Monday, [...]
NICE publishes advice on gammaCore for the treatment of cluster headache
22/10/2018
Report contributors agreed gammaCore was innovative and it has the potential to save money through the NHS by reducing the cost of treating cluster headache BASKING RIDGE, N.J., Oct. 22, 2018 (GLOBE NEWSWIRE) -- [...]
AC Immune Announces Dr. Andreas Muhs, Chief Scientific Officer, to Take Medical Leave of Absence
22/10/2018
Lausanne, Switzerland, October 22, 2018 - AC Immune SA (NASDAQ: ACIU), a Swiss-based, clinical-stage biopharmaceutical company with a broad pipeline focused on neurodegenerative diseases, today announced that Dr. [...]
Novartis COMBI-AD study of Tafinlar® + Mekinist® continues to demonstrate relapse free survival benefit in patients with BRAF V600-mutant stage III melanoma
22/10/2018
Extended follow up results confirm leading BRAF/MEK inhibitor combination Tafinlar + Mekinist continues to show relapse free survival benefit Cure rate modeling which estimates fraction of patients who may not relapse [...]
Biodesix Presents Positive Data in Detection of Primary Immunotherapy Resistance to Anti-PD-1 Therapy in Non-Small Cell Lung Cancer
22/10/2018
Serum Proteomic Test Could Optimize Treatment by Identifying Patients Unlikely to Benefit from Immunotherapy BOULDER, Colo. and MUNICH, Germany, Oct. 22, 2018 (GLOBE NEWSWIRE) -- Biodesix ® presented positive data for a [...]
Herantis Pharma Oyj: Manager's Transactions - Pekka Simula
22/10/2018
Herantis Pharma Oyj: Manager's Transactions - Pekka Simula Herantis Pharma Plc Company release 22 October 2018 at 9:00 am Herantis Pharma Oyj - Managers' Transactions ____________________________________________ Person [...]
Rule 2.9 Announcement
22/10/2018
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF THAT JURISDICTION. 22 October 2018 [...]
Director/PDMR Shareholding
22/10/2018
DXS INTERNATIONAL PLC Directors' Dealing The Board of DXS International plc (the “Company”), the NEX quoted clinical decision support developer and supplier of clinical decision support systems is pleased to confirm [...]
Award of Share Options
22/10/2018
Summit Therapeutics plc (‘Summit’ or the ’Company’) Award of Share Options Oxford, UK, and Cambridge, MA, US, 22 October 2018 – Summit Therapeutics plc (NASDAQ: SMMT, AIM: SUMM), a leader in new mechanism antibiotic [...]
DBV Technologies Announces Submission of Biologics License Application for Viaskin Peanut to the U.S. Food and Drug Administration
22/10/2018
Montrouge, France, October 22, 2018 DBV Technologies Announces Submission of Biologics License Application for Viaskin Peanut to the U.S. Food and Drug Administration DBV Technologies (Euronext: DB - ISIN: FR0010417345 [...]
DBV Technologies annonce le dépôt de sa demande d'autorisation de mise sur le marché de produit biologique (BLA) pour Viaskin Peanut auprès de la Food and Drug Administration des États-Unis
22/10/2018
Montrouge, France, le 22 octobre (07h30 CEST), 2018 DBV Technologies annonce le dépôt de sa demande d'autorisation de mise sur le marché de produit biologique (BLA) pour Viaskin Peanut auprès de la Food and Drug [...]
Addex Selective mGlu2 PAM ADX71149 Included in Review Highlighting Promising Investigative Drugs for Epilepsy (Review Published in Epilepsia Journal)
22/10/2018
Geneva, Switzerland, 2 October 2018 – Addex Therapeutics (SIX: ADXN), a leading company pioneering allosteric modulation-based drug discovery and development, announced today that its selective metabotropic glutamate [...]
Medtronic Co-Founder Earl Bakken Passes Away at Age 94
22/10/2018
DUBLIN - October 21, 2018 - Medtronic plc (NYSE:MDT) announced today that its co-founder, Earl E. Bakken, passed away peacefully on October 21, 2018 at his home on Kiholo Bay on the Big Island of Hawaii. He was 94 years [...]
Genmab Announces Positive Topline Results in Phase III CASSIOPEIA Study of Daratumumab in Front Line Multiple Myeloma
21/10/2018
Company Announcement Phase III CASSIOPEIA study of daratumumab in combination with bortezomib, thalidomide and dexamethasone in front line multiple myeloma met the primary endpoint of stringent Complete Response (sCR) [...]
G1 Therapeutics Presents Additional Data from Randomized Phase 2 Trial of Trilaciclib in Combination with Etoposide/Carboplatin for Treatment of First-Line Small Cell Lung Cancer
21/10/2018
New data analyses highlight myelopreservation and immune system benefits of trilaciclib in combination with chemotherapy Data presented at the European Society for Medical Oncology (ESMO) 2018 Congress RESEARCH TRIANGLE [...]
Loxo Oncology Announces Larotrectinib Clinical Update in Patients with TRK Fusion Cancers at the European Society for Medical Oncology 2018 Congress
21/10/2018
- Median Duration of Response Not Reached With One Year of Additional Follow-up - - 67 Newly Reported TRK Fusion Patients Exhibit 81% ORR - STAMFORD, Conn., Oct. 21, 2018 (GLOBE NEWSWIRE) -- Loxo Oncology, Inc. (Nasdaq [...]

Pages